The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab (R) applications given over an extended period (SMARTE-R-CHOP-14 trial of the DSHNHL).
Niels Murawski
No relevant relationships to disclose
Gerhard Held
No relevant relationships to disclose
Samira Zeynalova
No relevant relationships to disclose
Carsten Mueller
No relevant relationships to disclose
Viola Poeschel
Other Remuneration - Roche
Andreas Viardot
Honoraria - Roche
Mathias Haenel
No relevant relationships to disclose
Ulrich Keller
Consultant or Advisory Role - Roche
Honoraria - Roche
Marcel Reiser
No relevant relationships to disclose
Marita Ziepert
No relevant relationships to disclose
Norbert Schmitz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Michael Pfreundschuh
Consultant or Advisory Role - Amgen; Merck; Onyx; Pfizer; Roche